AbbVie and Merck Dividends Compared: Growth Potential Versus Patent Risk

AbbVie offers a higher dividend yield of 2.7% compared to Merck's 2.3%, with both companies having raised dividends approximately 5% last year, though Merck maintains a more conservative payout ratio of 52% of free cash flow versus AbbVie's 66%. AbbVie's growth drivers Skyrizi and Rinvoq are expanding at over 20% annually with U.S. patent protection through 2033, while Merck faces significant risk from Keytruda biosimilars launching in December 2028, with that drug representing roughly half of Merck's sales. Both companies have taken on substantial debt in recent acquisitions and typically announce dividend increases between late October and November.

Both pharmaceutical companies have pursued aggressive acquisition strategies recently, with AbbVie spending $10.9 billion on Apogee Therapeutics while simultaneously raising $18 billion in debt markets. Merck's spending spree was even larger, deploying approximately $26.4 billion across three separate acquisitions. These substantial debt accumulations reflect industry consolidation trends as major drugmakers seek to diversify their revenue streams and offset revenue losses from maturing products.

The timeline for dividend announcements appears consistent across both firms, typically occurring in the late October to November window. This predictability may be relevant for income-focused investors planning their portfolio adjustments. Both companies maintain strong interest coverage ratios, suggesting their debt levels remain manageable despite recent borrowing, though AbbVie's leverage position is noticeably higher than Merck's at present.